Table 1 Patients characteristics
Total N = 598 | ||
|---|---|---|
Age | ||
< 65 years, N (%) | 230(38.5) | |
≥ 65 years, N (%) | 368(61.5) | |
Gender | ||
Male, N (%) | 469(78.4) | |
Female, N (%) | 129(21.6) | |
Palliative setting | ||
Initially metastatic | 428(71.6) | |
Recurrent | 170(28.4) | |
Operation method | ||
Proximal gastrectomy | 60(35.3) | |
Distal gastrectomy | 83(48.8) | |
Total gastrectomy | 27(15.9) | |
Pathological type | ||
Well differentiated | 4(0.7) | |
Moderately differentiated | 59(9.8) | |
Poorly differentiated | 250(41.8) | |
Signet ring cell | 61(10.2) | |
Unassorted | 224(37.5) | |
Fecal occult blood# | ||
Positive | 129(33.9) | |
Negative | 381(74.7) | |
Combination of three regimens | 217(36.3) | |
Treatment response | N = 312 | |
Partial response | 14(4.49) | |
Stable disease | 169(54.17) | |
Progressive disease | 129(41.35) | |
Tumor location | ||
Upper part (U) | 253(42.3) | |
Middle part (M) | 91(15.2) | |
Lower part (L) | 206(34.4) | |
ML | 29(4.8) | |
MU | 19(3.2) | |
T/N stage | ||
Ia + Ib | 4 + 7(6.5) | |
IIa + IIb | 8 + 15(13.5) | |
IIIa+IIIb+IIIc | 34 + 46 + 56(80.0) | |
Hemoglobin level (g/L) | Initial | Post-treatment |
> 110 | 398 | 327 |
100–110 | 78 | 91 |
80–100 | 82 | 124 |
65–80 | 26 | 41 |
< 65 | 14 | 15 |
Manifestations of tumor hemorrhage | Initial | During treatment |
Fecal occult blood + | 37 | 47 |
Erosion and bleeding by endoscopy | 92 | 76 |
Hematemesis | 21 | 40 |
Iron deficiency anemia | 3 | 9 |
chemotherapy-induced anemia | 0 | 136 |
Unknown | 50 | 26 |
DIC | 0 | 5 |
Bone marrow infiltration | 0 | 4 |
Chemo regimens | ||
DCF | 217 | |
FOLFIRI | 152 | |
Paclitaxel liposome+Capecitabine/S-1 | 207 | |
XP | 264 | |
Single agent | 215 | |